AbbVie Aktie News

AbbVie's newer drugs and pipeline should help it address the biggest challenges it faces. Visa's services are in high demand, producing robust margins, and there's plenty of room to grow.

High-yield dividend stocks can be a red flag, but not always. Four companies in the S&P 500 offer huge dividends.

AbbVie has announced its acquisition of ImmunoGen for $10.1 billion in cash, marking a strategic move amidst rising competition for their leading treatment, Humira. ImmunoGen's Elahere, part of the innovative class of antibody-drug conjugates (ADC), specifically targets cancer cells, offering potential benefits in reducing toxicity for surrounding cells.

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.

AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the world of antibody-drug conjugates (ADC), which target cancer cells more precisely, potentially reducing harm to healthy cells. The deal is part of AbbVie's strategy to diversify its portfolio as its best-selling drug, Humira, faces increasing competition, but it also throws...

The pharmaceutical sector veteran announced its latest major asset buy. It has agreed to purchase one of its peers.

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.